TYRA-200

• Description :

  TYRA-200 is an orally active FGFR1/2/3 inhibitor. TYRA-200 shows dose-dependent tumor regression in both wild-type FGFR2 and FGFR2 mutant mice model. TYRA-200 can be used for advanced or metastatic intrahepatic cholangiocarcinoma and other FGFR2-driven solid tumors research[1].

• CAS Number :

  [2823289-77-4]

• UNSPSC :

  12352005

• Target :

  FGFR

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Concentration :

  10mM

• Purity :

  98.0500

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  C=CC(NC1=CC2=C(N(C=C2C)C3=C(C=NC(NC4=CN(N=C4)CC(C)(O)C)=N3)F)C=C1)=O

• Molecular Formula :

  C23H24FN7O2

• Molecular Weight :

  449.48

• References & Citations :

  [1]Rodon Ahnert J, et al. A multicenter, open-label, first-in-human study of TYRA-200 in advanced intrahepatic cholangiocarcinoma and other solid tumors with activating FGFR2 gene alterations (SURF201) [J]. 2025.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  FGF21; FGFR2; FGFR3